X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (158) 158
Publication (17) 17
Newspaper Article (15) 15
Book / eBook (10) 10
Book Chapter (3) 3
Book Review (2) 2
Dissertation (2) 2
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (65) 65
humans (61) 61
female (54) 54
oncology (43) 43
cancer (29) 29
middle aged (28) 28
adult (25) 25
ovarian cancer (25) 25
chemotherapy (24) 24
aged (20) 20
prognosis (18) 18
tumors (16) 16
male (15) 15
mutation (15) 15
breast cancer (14) 14
neoplasm staging (13) 13
analysis (12) 12
ovarian neoplasms - pathology (12) 12
surgery (12) 12
survival (12) 12
treatment outcome (12) 12
research (11) 11
retrospective studies (11) 11
adolescent (10) 10
carcinoma (10) 10
care and treatment (10) 10
clinical trials (10) 10
expression (10) 10
obstetrics & gynecology (10) 10
ovarian neoplasms - drug therapy (10) 10
patients (10) 10
abridged index medicus (9) 9
aged, 80 and over (9) 9
antineoplastic agents - therapeutic use (9) 9
bevacizumab (9) 9
medicine (9) 9
ovarian carcinoma (9) 9
ovarian neoplasms - genetics (9) 9
risk factors (9) 9
young adult (9) 9
disease-free survival (8) 8
genetic aspects (8) 8
health aspects (8) 8
pathology (8) 8
science (8) 8
multidisciplinary sciences (7) 7
neoplasm recurrence, local - pathology (7) 7
research article (7) 7
animals (6) 6
biomarkers (6) 6
carcinoma, ovarian epithelial (6) 6
cervical cancer (6) 6
drug therapy (6) 6
expansile (6) 6
families & family life (6) 6
follow-up studies (6) 6
gene expression (6) 6
genomes (6) 6
hematology, oncology and palliative medicine (6) 6
history (6) 6
immunohistochemistry (6) 6
immunotherapy (6) 6
medicine, general & internal (6) 6
neoplasm grading (6) 6
phenotype (6) 6
survival rate (6) 6
therapy (6) 6
abstracts (5) 5
antineoplastic agents - pharmacology (5) 5
apoptosis (5) 5
article (5) 5
chemotherapy, adjuvant (5) 5
child (5) 5
cisplatin (5) 5
dosage and administration (5) 5
endometrial neoplasms - pathology (5) 5
growth (5) 5
history and criticism (5) 5
hospitals (5) 5
life sciences (5) 5
metastases (5) 5
metastasis (5) 5
molecular targeted therapy (5) 5
neoplasms, glandular and epithelial - genetics (5) 5
pharmacokinetics (5) 5
platinum (5) 5
recurrence (5) 5
uterine cervical neoplasms - pathology (5) 5
adenocarcinoma (4) 4
american literature (4) 4
american literature history and criticism (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
behavior (4) 4
borderline tumors (4) 4
brachytherapy (4) 4
breast neoplasms - pathology (4) 4
breast-cancer (4) 4
cancer therapies (4) 4
children & youth (4) 4
combined modality therapy (4) 4
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (6) 6
UTL at Downsview - May be requested (5) 5
UofT at Scarborough - Stacks (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
Thomas Fisher Rare Book - Rare Book (2) 2
Art - Library use only (1) 1
Massey College (Robertson Davies) - Rare Book (1) 1
Robarts - Reference (1) 1
Royal Ontario Museum - Stacks (1) 1
Trinity College (John W Graham) - Stacks (1) 1
Trinity College (John W Graham) - Storage (1) 1
Victoria University E.J. Pratt - Reference (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 1, pp. 75 - 87
Summary Background Poly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian carcinomas with homologous recombination deficiency. Along with BRCA1... 
Hematology, Oncology and Palliative Medicine | POLY(ADP-RIBOSE) POLYMERASE | OLAPARIB | ONCOLOGY | HOMOLOGOUS RECOMBINATION DEFICIENCY | MUTANT-CELLS | DNA-REPAIR | CANCER | HETEROZYGOSITY | TUMORS | BREAST | GENOMIC LOSS | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Germ-Line Mutation - genetics | Neoplasm Recurrence, Local - pathology | Ovarian Neoplasms - genetics | Neoplasms, Glandular and Epithelial - genetics | Peritoneal Neoplasms - drug therapy | Fallopian Tube Neoplasms - genetics | Female | Antineoplastic Agents - pharmacology | Poly(ADP-ribose) Polymerases - chemistry | Ovarian Neoplasms - drug therapy | Platinum - pharmacology | Fallopian Tube Neoplasms - drug therapy | Peritoneal Neoplasms - pathology | Neoplasms, Glandular and Epithelial - pathology | Fallopian Tube Neoplasms - pathology | Survival Rate | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | BRCA1 Protein - genetics | International Agencies | Peritoneal Neoplasms - genetics | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Indoles - therapeutic use | Neoplasm Recurrence, Local - genetics | Aged | Neoplasm Staging | BRCA2 Protein - genetics | Drug Resistance, Neoplasm - drug effects | Sugars | Monosaccharides | Ovarian cancer | Analysis | Carcinoma | Cancer
Journal Article
Bulletin du Cancer, ISSN 0007-4551, 11/2017, Volume 104, Issue 11, pp. 971 - 980
The demonstration of frequent defects in the DNA damage response in high grade ovarian cancer has paved the way for a new therapeutic approach aimed at... 
DNA damage | Poly-ADP ribose polymerase inhibitors | DNA repair | Gynaecological cancers
Journal Article
by Coleman, Robert L and Coleman, R L and Oza, Amit M and Oza, A M and Lorusso, D and Lorusso, Domenica and Aghajanian, C and Aghajanian, Carol and Oaknin, A and Oaknin, Ana and Dean, A and Dean, Andrew and Colombo, N and Colombo, Nicoletta and Weberpals, Johanne I and Weberpals, J I and Clamp, Andrew and Clamp, A and Scambia, Giovanni and Scambia, G and Leary, A and Leary, Alexandra and Holloway, Robert W and Holloway, R W and Gancedo, M Amenedo and Gancedo, Margarita Amenedo and Fong, Peter C and Fong, P C and Goh, Jeffrey C and Goh, J C and O'Malley, David M and O'Malley, D M and Armstrong, Deborah K and Armstrong, D K and Garcia-Donas, Jesus and Garcia-Donas, J and Swisher, E M and Swisher, Elizabeth M and Floquet, A and Floquet, Anne and Konecny, Gottfried E and Konecny, G E and McNeish, I A and McNeish, Iain A and Scott, C L and Scott, Clare L and Cameron, Terri and Maloney, Lara and Isaacson, Jeff and Goble, Sandra and Grace, Caroline and Harding, Thomas C and Raponi, Mitch and Sun, James and Lin, Kevin K and Giordano, Heidi and Ledermann, J A and Ledermann, Jonathan A and Buck, M and Friedlander, M L and Harnett, P and Kichenadasse, G and Denys, H and Dirix, L and Vergote, I and Elit, L and Ghatage, P and Plante, M and Provencher, D and Welch, S and Gladieff, L and Joly, F and Lortholary, A and Lotz, J and Medioni, J and Tredan, O and You, B and El-Balat, A and Hänle, C and Krabisch, P and Neunhöffer, T and Pölcher, M and Wimberger, P and Amit, A and Kovel, S and Leviov, M and Safra, T and Shapira-Frommer, R and Stemmer, S and Bologna, A and Pignata, S and Sabbatini, R F and Tamberi, S and Zamagni, C and O'Donnell, A and Herraez, A Casado and Guerra, E M and Palacio, I and Romero, I and Sanchez, A and ... and ARIEL3 Investigators and ARIEL3 investigators
The Lancet, ISSN 0140-6736, 10/2017, Volume 390, Issue 10106, pp. 1949 - 1961
Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbouring a mutation or high percentage of... 
MEDICINE, GENERAL & INTERNAL | MULTICENTER | SOLID TUMORS | BEVACIZUMAB | OPEN-LABEL | CANCER | HETEROZYGOSITY | EPITHELIAL OVARIAN | CHEMOTHERAPY | Double-Blind Method | Follow-Up Studies | Risk Assessment | Humans | Middle Aged | Ovarian Neoplasms - pathology | Neoplasm Recurrence, Local - drug therapy | Survival Rate | Treatment Outcome | Ovarian Neoplasms - mortality | Neoplasm Recurrence, Local - mortality | Indoles - administration & dosage | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Neoplasm Recurrence, Local - pathology | Disease-Free Survival | Maintenance Chemotherapy - methods | Internationality | Ovarian Neoplasms - therapy | Female | Aged | Molecular Targeted Therapy - methods | Clinical trials | Care and treatment | Carcinoma | Drug therapy | Ovarian cancer | Cancer | Analysis | Chemotherapy | Ovarian carcinoma | Platinum | Biomarkers | Mutation | Cancer therapies | Tumors | Homologous recombination | Central nervous system | Poly(ADP-ribose) | Homology | Genomes | Fallopian tube | ADP | Anticancer properties | Metastases | Homologous recombination repair | Randomization | Pain | Motivation | Ribose | Hemoglobin | Alanine | Anemia | Poly(ADP-ribose) polymerase | Breast cancer | Patients | Survival | Heterozygosity | Abdomen | Polymerase | Inhibitors | Point mutation | Loss of heterozygosity | Antitumor activity | Aspartate aminotransferase | Peritoneum
Journal Article
Obstetrical & Gynecological Survey, ISSN 0029-7828, 09/2019, Volume 74, Issue 9, pp. 530 - 532
(Abstracted from N Engl J Med 2019;380:1256–1266)Mucinous ovarian cancer is a rare form of epithelial ovarian cancer, accounting for approximately 3% of all... 
Rare diseases | Physiological aspects | Care and treatment | Diagnosis | Ovarian cancer
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 10/2017, Volume 76, Issue 10, pp. 1747 - 1750
ObjectivesImmune checkpoint inhibitors (ICIs) targeting cytotoxic T-lymphocyte-associated protein 4 and programmed cell death protein 1 (PD-1) have... 
MELANOMA | MANAGEMENT | TOXICITIES | LEAGUE | COLLEGE | RHEUMATOLOGY | NIVOLUMAB | BLOCKADE | CLASSIFICATION CRITERIA | CANCER | IPILIMUMAB | Antibodies, Monoclonal, Humanized - adverse effects | Polymyalgia Rheumatica - blood | Polymyalgia Rheumatica - chemically induced | Arthritis, Rheumatoid - blood | Humans | Ipilimumab | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Peptides, Cyclic - immunology | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Arthritis, Rheumatoid - chemically induced | Polymyalgia Rheumatica - drug therapy | B7-H1 Antigen - antagonists & inhibitors | Antineoplastic Agents - adverse effects | Arthritis, Rheumatoid - drug therapy | Aged, 80 and over | Antibodies - blood | Female | Aged | Retrospective Studies | CTLA-4 Antigen - antagonists & inhibitors | Corticoids | Disease | PD-1 protein | Arthralgia | Lung cancer | Clinical trials | Antibodies | Cytotoxicity | Mesothelioma | Lymphocytes T | Metastasis | Cancer therapies | Immunosuppressive agents | Proteins | Immunotherapy | Rheumatism | Immunoglobulins | Antiinflammatory agents | Cell survival | Psoriasis | Internal medicine | Rheumatic diseases | Rheumatology | Melanoma | Inflammation | Citrulline | Patients | Rheumatoid factor | Immune checkpoint | Cell death | Rheumatoid arthritis | Collaboration | Polymyalgia rheumatica | Ligands | Autoimmune diseases | Apoptosis | Cancer
Journal Article
Journal Article